Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose 90Y-Labetuzumab Radioimmunotherapy in Stage IV Breast Cancer
NCT00004085Phase 2Completed
- Sponsor
- Garden State Cancer Center
- Start
- May 1998
- Primary completion
- May 2002
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of yttrium-90 labetuzumab in breast cancer, sponsored by Garden State Cancer Center. Started May 1998; status: completed.
02
Drugs
yttrium-90 labetuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00004085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004085.